Merck's Sponsors symposium

3

A place for POSEIDON: Assisting low prognosis patients Dr Victoria Sephton, Group Medical Director, Care Fertility Group

Presentation will cover:

  • A brief review of the need for a new classification criteria, the creation of the POSEIDON criteria and its importance in low prognosis patients
  • Understand the role of the 4 POSEIDON categories in clinical practice for the diagnosis and management of low prognosis patients
  • Explore the future of the POSEIDON classification in clinical practice, including its use in randomised controlled trials

Vicky has over 20 years’ experience in diagnosing and managing infertility.  She was trained in reproductive medicine and assisted conception by Professor Kingsland at The Hewitt Centre Liverpool 1998. Subsequently, she was appointed as Lead Consultant for the Acute Gynaecology & Fertility Service at Warrington & Halton NHS FT, where she established the satellite IVF service at Halton. She was appointed Medical Director for Assisted Conception Services at The Countess of Chester Hospital (now CARE Fertility Chester) in January 2019.  During this time, in addition to working for Care, she was dedicated to helping the next generation of Obstetricians & Gynaecologists achieve excellence with her role as a Training Programme Director and Less Than Full Time O&G specialty lead for Health Education North West. Since March 2022, Vicky has been delivering the role of Group Medical Director and GMC Responsible Officer for Care Fertility, which has seen her responsible for medical leadership, clinical performance and excellence for 8 clinics in the North of UK. She chairs clinical focus groups responsible for reviewing and setting group policy, and has particular interest in supporting and guiding clinical training and development, management of recurrent failure and low prognosis patients.

4

Unravelling the evidence: Strategies to optimise outcomes for low prognosis patients Dr Alberto Vaiarelli, Gynaecologist and Medical Scientific Coordinator, GeneraLife Roma, Italy

Presentation will cover:

  • To explain how stratifying patients through POSEIDON can rationalise the need for alternative treatment strategies for low prognosis patients
  • To share experience on the benefits and limitations of current and future treatment options for patients with low prognosis
  • To discuss the current evidence on DuoStim and review which patients may benefit most from this treatment strateg

Dr Alberto Vaiarelli is a gynaecologist and fertility specialist and is Medical Scientific Coordinator of GeneraLife Rome. He completed a clinical observership at Yale University and was a clinical fellow at the Centre for Reproductive Medicine of UZ Brussels. He obtained a PhD and became a post-doctoral Fellow in Reproductive Endocrinology at the University of Messina. He obtained two Masters in reproductive medicine, andrology and assisted reproductive technology. An author and co-author of more than 80 original research papers and reviews published in peer-reviewed journals. In 2018, he achieved the National Certification as Associate Professor and in 2021 as Full Professor of Obstetrics and Gynaecology. Dr Vaiarelli is internationally recognised for his expertise in reproductive medicine. His scientific work is primarily focused on the management of low prognosis patients and on the improvement of efficacy and efficiency in IVF.